We previously reported that analysis of histologically normal intestinal epithelium for spectral slope, a marker for aberrations in nanoscale tissue architecture, had outstanding accuracy in identifying field carcinogenesis in preclinical colorectal cancer models. In this study, we assessed the translatability of spectral slope analysis to human colorectal cancer screening.
T he lack of an inexpensive, minimally intrusive, and sensitive colorectal cancer (CRC) screening test has contributed to the continued high mortality rate from this malignancy in the United States. 1 Many CRC screening techniques are based on exploiting the "field effect" concept of colon carcinogenesis. 2 The proposition that the genetic/environmental milieu that leads to neoplastic lesions in one area of the colon should be detectable, in some form, throughout the colon. 3 Thus, assessing the easily accessible mucosa (i.e., rectosigmoid) should potentially allow risk assessment of the entire colon. Indeed, several reports have demonstrated that profound genetic and cellular changes exist in the microscopically normal mucosa of patients who harbor CRC. 4 However, the most-widely clinically utilized marker of the field effect, the distal adenoma detected by flexible sigmoidoscopy, lacks both adequate sensitivity and positive predictive value. 5, 6 Therefore, finding accurate, practical means of identifying field changes would be of great clinical importance. 7 Members of our group have pioneered the use of light-scattering technologies for detection of subtle cell structural changes during neoplastic progression. 8, 9 Recently, we have developed four-dimensional elastic lightscattering fingerprinting (4D-ELF) that allows quantitative assessment of the nanoscale tissue architecture. 10, 11 Infor-mation on particle sizes ranging from macromolecular complexes to small organelles has been harnessed through a spectroscopic parameter termed spectral slope. Our group has previously demonstrated that in the histologically normal colonic mucosa of the azoxymethane (AOM)-treated rat model, spectral slope was markedly altered prior to development of the earliest conventional markers of colon carcinogenesis such as aberrant crypt foci (ACF) or adenomas. 10 Furthermore, we have reported that spectral slope from the normal intestinal mucosa of the MIN mouse, a genetic model that replicates familial adenomatous polyposis, was markedly suppressed prior to the occurrence of adenomas. 12 These findings with spectral slope clearly out-perform any previous biomarkers for colon carcinogenesis. In the present study, we explore the translatability of spectral markers to human colon carcinogenesis by assessing the spectral slope from the normal epithelium obtained during colonoscopy.
METHODS AND MATERIALS
All studies were performed in accordance with the Institutional Review Board of Evanston-Northwestern Healthcare. Patients were eligible for the study if they were undergoing colonoscopy at Evanston Hospital for colon neoplasia detection, predominantly average-risk screening with a smaller subset for evaluation of hematochezia of guaiac-positive stools. The exclusion criteria included incomplete colonoscopy, poor preparation, and coagulopathy, personal or family history of colon neoplasia, or colitis. Two colonic biopsies were obtained from endoscopically normal midtransverse mucosa irrespective of findings on colonoscopy. However, all biopsies were taken at least 5 cm away from any neoplastic lesion. Biopsies were placed in phosphate buffered saline and subjected to 4D-ELF analysis. Approximately ten 4D-ELF measurements per subject were obtained. The histologic diagnosis was confirmed through independent review by a study pathologist (CH). Advanced adenomas were defined by size greater than 1 cm, more than 25 percent villous component or high-grade dysplasia.
Size Distribution Analysis and Spectral Slope Determination 4D-ELF analysis was performed by investigators blinded to clinical findings as previously described. 10, 12 The spectra, computationally simulated using Mie theory, were fit to the spectra acquired by 4D-ELF after averaging over scattering angle from 0 to 5 degrees and azimuth angle 0 degrees using the conventional least-squares minimization algorithm. As previously reported, the lognormal size distributions provided fits superior to those obtained using other types of size distribution. The outcome of the fitting procedure was the determination of the mean size and the standard deviation of the tissue structures that gave rise to the scattering signal. Spectral slope was defined as the absolute value of the coefficient of the linear fit of variation in spectral variation ΔI(λ) using linear regression analysis. 10, 12 Statistical Analysis Values for spectral slope were analyzed using a two-sided Student's t-test. For the estimate of performance characteristics, patients with negative colonoscopies and nonadvanced adenomas were divided equally into a training and a testing set. Given the small number of patients with advanced adenomas, we decided to train on nonadvanced adenomas and test on advanced adenomas. The training set had 59 patients whereas the testing set had 68 patients (58 controls/nonadvanced adenomas and 10 advanced adenomas). Thus, the threshold value of normal/abnormal was determined for negative colonoscopy vs. nonadvanced adenoma and tested on the negative colonoscopy vs. advanced adenoma. The thresholds in the training set were designed to optimize sensitivity at the expense of specificity. No significant difference in age or gender distribution were found between the training and testing set.
RESULTS

Patient Characteristics
We recruited 127 patients (66 males and 61 females), 86 patients were without neoplasia and 41 harbored adenomas. Advanced adenomas were designated in 10 of 41 patients based on tumor size greater than 1 cm. The mean age of patients who were neoplasia-free was 55.2 years (SD, 9.0), with adenomas 58.3 years (SD, 8.5) and with advanced adenomas 62.4 years (SD, 12.1).
Intracellular Size Distribution
Representative size distributions of intracellular structures obtained from biopsies of the endoscopically normal midtransverse colonic mucosa are demonstrated in Fig. 1 . When compared to those who were neoplasia-free, patients who harbored adenomas had an increased propensity for larger sized particles, e.g., greater than 0.1 μm, with a corresponding decrease in smaller particles, e.g., less than 0.05 μm. This trend was even more striking in patients harboring advanced adenomas.
Spectral Slope
Spectral slope was calculated as a marker for the heterogeneity of submicron particle size. The spectral slope of subjects without neoplasia was 0.072±0.004 (Fig. 2) . In patients with adenomas, the spectral slope decreased to 0.039±0.003 representing decreased relative proportion of small particles with a concomitant increase in the proportion of large particles (P≤0.00001 vs. control subjects). Moreover, in the subset of patients with advanced adenomas, spectral slope was further decreased to 0.023±0.006 (P≤0.00001 vs. control subjects).
Effect of Adenoma Location and Patient Age on Spectral Slope
For spectral slope to be useful for CRC screening, it would be important for this marker from one segment of the colon to reflect neoplasia throughout the organ. No evidence of diminution of the median spectral slope field based on distance from biopsy (Fig. 3) . Specifically, ANOVA analysis was not markedly different in patients with adenoma located in the right colon, transverse colon, or left colon (P=0.14). Moreover, a statistically significant difference in mean spectral slope was observed in adenoma-harboring patients irrespective of adenoma location when compared to adenoma-free patients (unadjusted paired t-test).
With regard to potential confounders, age was felt to be important given it is one of the most powerful CRC risk factors. As previously noted, neoplasia patients were slightly older than controls. When the subjects were stratified by colonoscopic findings and age, i.e., older than 60 years and less than 60 years, no evidence was found of a relationship between spectral slope and increase age per se: neoplasia-free patients, P=0.372; adenoma-harboring patients, P=0.388; advanced adenoma patients, P=0.598. Furthermore, ANOVA analysis of age compared to spectral slope was not statistically significant (P=0.39).
Performance Characteristics
Performance ability of the spectral slope to predict advanced adenomas was assessed using histologically normal mucosa. Advanced adenomas were chosen because these lesions are clearly clinically and biologically significant in contrast with most diminutive adenomas. Moreover, the colonoscopic miss rate is significant for small adenomas at approximately 25 percent, but low for advanced adenomas at approximately 2 percent. 13 Using threshold positive/negative values derived from a training set on nonadvanced adenomas, we calculated that spectral slope had a sensitivity of 60 percent, specificity of 93 percent. The spectral slope positive predictive value is 50 percent and negative predictive value is 95 percent for advanced adenomas. Receiver operator characteristic curve analysis compared no dysplasia with FIGURE 2. Four-dimensional elastic light-scattering fingerprinting (4D-ELF) spectral slope from endoscopically-normal mucosa is altered in patients with neoplasia. (Fig. 4) . Given the modest number of advanced adenomas (n=10), these performance characteristics should be viewed as a preliminary estimate.
DISCUSSION
As the first clinical demonstration of the ability of 4D-ELF analysis from one area of endoscopically normal mucosa to identify concurrent neoplasia elsewhere in the colon, the translatability of our previous work from experimental models to humans is confirmed. The spectral slope was markedly suppressed in subjects who harbored colonic adenomas when compared with those who were neoplasia free. Importantly, the spectral slope suppression was unrelated to the location of the lesion supporting the robustness of this marker for identifying the field effect. While the modest number of patients would lead us to emphasize the pilot nature of this data, it does serve as an important proof of principle confirmation to the screening approach. The concept of field effect in colon carcinogenesis is well established. For instance, from a morphologic perspective, the number of rectal ACF correlated with adenomas and carcinoma occurrence in the proximal colon.
14 Profound cellular alterations, e.g., altered apoptosis and proliferation rates, in the histologically normal mucosa of patients harboring neoplasia have been demonstrated. 15, 16 From a genetic/epigenetic perspective, Chen and colleagues noted dramatic overexpression of proto-oncogenes such as cyclooxygenase 2 and osteopontin in both the tumors and the histologically normal mucosa at some distance from the tumors. 4 Furthermore, other groups have noted that loss of insulin growth factor-1 imprinting in the endoscopically normal mucosa accurately identified risk of colonic neoplasia. 17 In addition, the proteomic profile from histologically normal mucosa from patients harboring colonic neoplasia has been recently shown to be quite distinct from profiles of neoplasia-free patients. 18 These genetic/epigenetic alterations would be expected to have microarchitectural consequences; however, devising a reliable methodology has not, to date, been possible. 4D-ELF allows, for the first time, a practical means of probing cellular microarchitecture. We have reported in experimental models that the profound early changes in spectral markers in colon carcinogenesis can be reversed by targeting specific proto-oncogenes thereby supporting the geneticmicroarchitectural relationship of the field effect. 19 Our development of 4D-ELF has allowed us quantification of submicron particle size through the use of spectral markers. As indicated from the size-distribution data ( Fig. 1) , an increase in the number of larger particle sizes (e.g., size greater than 0.05 μm) with a concomitant decrease in the number of smaller particles (e.g., size less than 0.1 μm) was observed in patients who harbored adenomas and advanced adenomas when compared with those who were neoplasia free. Therefore, the corresponding spectral slope values, which represent the heterogeneity in particle size, was markedly reduced in these patients. Our findings in this clinical study are consistent with our previous studies showing that altered size distribution preceded the conventional biomarkers of colon carcinogenesis in experimental models. 10, 12 We need to reiterate that these measures were taken from the histologically normal mucosa and thus were not related to dysplasia.
Our findings indicate that spectral slope was able to identify subjects at risk of concurrent colon neoplasia with reasonable accuracy. The performance characteristics of spectral slope for advanced adenomas were modest with a negative predictive value of 95 percent and positive predictive value of 50 percent and an area under the ROC curve of 0.80. This single marker compares favorably to currently used clinical tests such as fecal occult blood tests and fecal DNA analysis which has a negative predictive value less than 80 percent and a positive predictive value near 50 percent for advanced adenomas and carcinomas. 20 From a risk-stratification perspective, the strong negative predictive ability is of paramount importance, because the consequence of a false-positive result is minimal, i.e., undergoing a colonoscopy which current guidelines state is an indicated procedure for the entire average risk populations, whereas having a false-negative could be clinically disastrous, i.e., patient does not undergo further testing and develops colon cancer. This initial report on a single spectral marker, encompassing less than 5 percent of the information available from light scattering signatures, supports the promise of 4D-ELFbased screening in clinical practice. Use of multiple spectral markers could improve diagnostic accuracy. In experimental models, we have demonstrated that use of a panel of markers increased performance characteristics to greater than 95 percent. 10, 12 Limitations of this study include the modest number of patients and the lack of CRCs. Additionally, in any colonoscopy-based study, the potential for missed adenomas must be considered, estimated to be 27 percent. 15 To mitigate this issue, we focused on advanced adenomas, where the detection rate is 98 percent, for calculation of performance characteristics. 13 Another issue is that we only assessed spectral slope from a single colon region so the reproducibility in other areas, especially the more readily accessible rectal mucosa, needs to be explored in future larger studies. In this regard, given that spectral slope was decreased irrespective of location of the adenomas suggests that assessment of the rectal mucosa may be potentially informative about lesions throughout the colon. The need for biopsies may be undesirable for population screening; therefore future studies will employ a recently developed fiber-optic probe that can measure spectral slope in situ (unpublished data). Confounding by CRC risk factors is potential concern. Age is the most powerful risk factor for sporadic colonic neoplasias, 2 but age was not a confounding factor on spectral slope values. We did not assess other CRC risk factors including obesity, tobacco, or alcohol use 20 ; however, it is unlikely that these factors are important enough to bias our results. Finally, spectral slope represents a minute fraction of the information encoded in light-backscattering. Therefore, a panel of 4D-ELF markers could out-perform the assessment of spectral slope alone. However, our data indicates that spectral slope by itself is a useful marker for advanced adenomas, although the modest numbers in this study means this data should be construed as pilot in nature.
CONCLUSION
Our report serves as proof-of-principle that spectral markers from the normal colonic mucosa can predict neoplasia risk in humans. Given the outstanding performance in experimental models, this approach has promise for human CRC screening. Future studies will be conducted to assess the performance of a panel of spectral markers in different regions of the colon. Our long-term goal would envision the use of spectral markers for longterm risk stratification, thus enabling the individualized patient recommendations regarding the modality and intensity of CRC screening.
